Arbor Pharmaceuticals LLC-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Arbor Pharmaceuticals LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8010843
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月20日
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Arbor Pharmaceuticals LLC (Arbor) is a healthcare products provider that develops prescription products for the hospital, cardiovascular and pediatric segments. The company offers licensing, manufacturing, development and commercialization of late-stage prescription products. It also offers generic prescription and development stage products. Arbor’s prescription products comprise edarbi, edarbyclor, bidil, nymalize, eryped, and erythromycin group of products. It offers products used in treatment areas including cardiovascular, emergency, pediatrics, psychiatry and endocrinology diseases. The company offers its products through sales professionals to hospitals and physicians across the US. Arbor is headquartered in Atlanta, Georgia, the US.

Arbor Pharmaceuticals LLC – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Arbor Pharma To Acquire US Rights For Gliadel Wafer From Eisai 11
Private Equity 13
KKR to Acquire Minority Stake in Arbor Pharma 13
Partnerships 14
Debiopharm Enters into Distribution Agreement with Arbor Pharma 14
Licensing Agreements 15
Dr. Reddy’s Labs Enters into Licensing Agreement with XenoPort for XP23829 15
Reckitt Benckiser Pharma Enters Into Licensing Agreement With XenoPort For Arbaclofen Placarbil 16
Takeda Pharma Enters Into Licensing Agreement With Arbor Pharma For Edarbi And Edarbyclor 17
Equity Offering 18
XenoPort Files Shelf Registration Statement for Public Offering of Shares For USD150 Million 18
XenoPort Completes Public Offering Of Shares For US$85.8 Million 19
XenoPort Completes Public Offering Of Common Stock For US$46 Million 20
Debt Offering 21
XenoPort Raises USD115 Million in Private Placement of 2.5% Notes Due 2022 21
Acquisition 23
Fosun International and Shanghai Pharma May Acquire Arbor Pharma 23
Arbor Pharma Acquires Shares of XenoPort in a Tender Offer 24
Arbor Pharmaceuticals LLC – Key Competitors 26
Arbor Pharmaceuticals LLC – Key Employees 27
Arbor Pharmaceuticals LLC – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Key Facts 2
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Arbor Pharmaceuticals LLC, Deals By Therapy Area, 2011 to YTD 2017 8
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Arbor Pharma To Acquire US Rights For Gliadel Wafer From Eisai 11
KKR to Acquire Minority Stake in Arbor Pharma 13
Debiopharm Enters into Distribution Agreement with Arbor Pharma 14
Dr. Reddy's Labs Enters into Licensing Agreement with XenoPort for XP23829 15
Reckitt Benckiser Pharma Enters Into Licensing Agreement With XenoPort For Arbaclofen Placarbil 16
Takeda Pharma Enters Into Licensing Agreement With Arbor Pharma For Edarbi And Edarbyclor 17
XenoPort Files Shelf Registration Statement for Public Offering of Shares For USD150 Million 18
XenoPort Completes Public Offering Of Shares For US$85.8 Million 19
XenoPort Completes Public Offering Of Common Stock For US$46 Million 20
XenoPort Raises USD115 Million in Private Placement of 2.5% Notes Due 2022 21
Fosun International and Shanghai Pharma May Acquire Arbor Pharma 23
Arbor Pharma Acquires Shares of XenoPort in a Tender Offer 24
Arbor Pharmaceuticals LLC, Key Competitors 26
Arbor Pharmaceuticals LLC, Key Employees 27
Arbor Pharmaceuticals LLC, Subsidiaries 28

★海外企業調査レポート[Arbor Pharmaceuticals LLC-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sejal Glass Limited (SEZAL):企業の財務・戦略的SWOT分析
    Sejal Glass Limited (SEZAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Advance Syntex Ltd:企業の戦略的SWOT分析
    Advance Syntex Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Hybrigenics SA (ALHYG):製薬・医療:M&Aディール及び事業提携情報
    Summary Hybrigenics SA (Hybrigenics) is a biopharmaceutical company that develops new targets and therapies against proliferative and non-cancerous diseases. Its lead product candidate Inecalcitol, is a vitamin D receptor agonist being assessed for various cancer indications including prostate cance …
  • Livescribe Inc:企業の戦略的SWOT分析
    Livescribe Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Alabama Power Co:企業の発電所・SWOT分析2018
    Alabama Power Co - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (e …
  • Starkey Hearing Technologies Inc:企業の戦略的SWOT分析
    Starkey Hearing Technologies Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Sumitomo Heavy Industries, Ltd.:企業の戦略・SWOT・財務情報
    Sumitomo Heavy Industries, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Sumitomo Heavy Industries, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Mercy Health:企業の戦略的SWOT分析
    Mercy Health - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • University of Maryland Medical Center Corp:企業の戦略的SWOT分析
    University of Maryland Medical Center Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors an …
  • Publix Super Markets, Inc.:企業の戦略・SWOT・財務分析
    Publix Super Markets, Inc. - Strategy, SWOT and Corporate Finance Report Summary Publix Super Markets, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Minerals Technologies Inc (MTX):企業の財務・戦略的SWOT分析
    Minerals Technologies Inc (MTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • AeroMaoz Ltd.:企業の戦略・SWOT・財務情報
    AeroMaoz Ltd. - Strategy, SWOT and Corporate Finance Report Summary AeroMaoz Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Debiotech SA-医療機器分野:企業M&A・提携分析
    Summary Debiotech SA (Debiotech) is a medical device company that develops therapeutic devices and diagnostic products. The company’s products include patch-pump, injection, multi-fluidic cassette type system, infusion pump and microsystems. It develops products in the areas of implantable and exter …
  • juwi AG:企業の戦略的SWOT分析
    juwi AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • The Chemours Company LLC:企業の戦略・SWOT・財務情報
    The Chemours Company LLC - Strategy, SWOT and Corporate Finance Report Summary The Chemours Company LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • AnaMar AB:製薬・医療:M&Aディール及び事業提携情報
    Summary AnaMar AB (AnaMar), a subsidiary of Koncentra Holding AB, is a drug discovery company that discovers, develops and commercializes therapeutic strategies to treat debilitating inflammation, fibrosis and pain. The company develops drug candidates from several chemical classes on the receptors …
  • BSN medical GmbH:企業の戦略的SWOT分析
    BSN medical GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • PPL Corporation (PPL):石油・ガス:M&Aディール及び事業提携情報
    Summary PPL Corp (PPL) is an energy holding company. Through its subsidiaries, LG&E, Kentucky Utilities, and KU Energy, it generates, transmits, distributes, and sells electricity; and distributes and sells natural gas. The company produces electricity from coal, natural gas, oil, hydro, and solar s …
  • Croatia Airlines d.d.:企業の戦略・SWOT・財務情報
    Croatia Airlines d.d. - Strategy, SWOT and Corporate Finance Report Summary Croatia Airlines d.d. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • OCI Co Ltd (010060):電力:M&Aディール及び事業提携情報
    Summary OCI Co Ltd (OCI) is a green energy and chemical company. It manufactures and sells a wide range of inorganic chemicals, coal and petrochemicals, and fine chemicals. The company’s product portfolio includes toluene di-isocyanate (TDI), hydrogen peroxide, carbon black, pitch, sodium percarbona …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆